Committee on Population Screening

The task of the Committee on Population Screening is twofold: to identify developments in population screening and assess permit applications in connection with the Population Screening Act.

Identifying developments

Considerable attention is given to the early detection of diseases and research into risk factors. Scientific developments are occurring at a rapid rate. This has consequences for existing screening programmes and can provide opportunities for new ones. The Health Council of the Netherlands monitors these developments and their potential consequences (in the nature of the advisory report Screening: between hope and hype) and reports on them. Activities in this context can range from monitoring developments in the area of screening tests to reporting on ethical issues.

Assessing permit applications

The Health Council of the Netherlands has a statutory duty to assess permit applications in connection with the Population Screening Act. The Minister of Health, Welfare and Sport decides on such applications. The Population Screening Act was put into effect on July First 1996 and is intended to protect people from population screening studies that could pose a risk to health. The Population Screening Act provides for a permit system for population screening involving the use of ionising radiation, concerning cancer or concerning serious diseases or abnormalities for which no treatment is possible. Permit applications can concern a national population screening program or changes therein, or scientific research in a population screening that may or may not be nationally implememnted.

This activity is a permanent part of the Prevention focus area.

The membership of the committee may differ from one advice to another. Because a permanent committee addresses more than one topic, potential conflicts of interests of committee members will be re-evaluated at the start of each advisory process. The composition of the Committee by advice can be found on the last page of the advisory report.

Members

  • Prof. dr. J. Gussekloo, Professor in General Medicine, Leiden University Medical Center, Leiden, chairperson
  • Prof. dr. O.M. Dekkers, Professor in Clinical Epidemiology; Specialist in Internal Medicine, Leids Universitair Medisch Centrum, Leiden, vice chairperson
  • Dr. E.M.M. Adang, Health Economist, Radboud University, Nijmegen
  • Prof. dr. M.C. Cornel, Professor of Community Genetics and Public Health Genomics, Amsterdam UMC
  • Dr. W.J. Dondorp, Ethicist, Maastricht University Medical Centre, Maastricht
  • Dr. mr. Y. Drewes, Physician, Coordinator Master Vitality and Ageing, Leids Universitair Medisch Centrum, Leiden
  • Dr. P.J.M. Elders, Assistant Professor, Department of General Practice and Elderly Care and the EMGO Institute for Health and Care Research, Amsterdam UMC
  • Prof. dr. C.H. van Gils, Professor Clinical Epidemiology of Cancer at Universitair Medisch Centrum Utrecht
  • Prof. dr. I.M. van Langen, Professor in Clinical Genetics, University Medical Center Groningen
  • Prof. dr. B.J.C. Middelkoop, Professor in Public Health, Leiden University Medical Center, Leiden
  • Mr. dr. M.C. Ploem, Lecturer of Health Law, Amsterdam UMC
  • Dr. J.J. van Tol-Geerdink, Researcher Shared Decision Making in Oncology, Radboud University, Nijmegen

Observers:

  • Mr. M.G. Kleefkens, Ministry for Health, Welfare and Sport, The Hague
  • A.J.J. Lock, National Institute for Public Health and the Environment, Bilthoven
  • R. van Tol, Ministry for Health, Welfare and Sport, The Hague

Scientific Secretaries:

  • Dr. J.D. van der Berg, Health Council, The Hague
  • Dr. M.J. Emaus, Health Council, The Hague
  • Mr. dr. R.E. van Hellemondt, Health Council, The Hague
  • Dr. L.G.M. van Rossum, Health Council, The Hague